This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunologic Disorders  • Headache  • Multiple Sclerosis/ Demyelinating Disease  • Neurology, Other  • Alert me on articles by topic

Olaf Stüve, MD, PhD; Petra D. Cravens, PhD; Mahendra P. Singh, PhD; Elliot M. Frohman, MD, PhD; J. Theodore Phillips, MD, PhD; Gina Remington, RN, BSN; Wei Hu, MD, PhD; Bernhard Hemmer, MD; Michael J. Olek, DO; Nancy L. Monson, PhD; Michael K. Racke, MD

Arch Neurol. 2007;64(7):1055-1056.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The reported frequency of post–lumbar puncture headache (PLPH) is as high as 70%.¹ In contrast, the frequency of PLPH with an atraumatic 22-gauge Sprotte needles is 12.2%.²

Natalizumab (Tysabri; Biogen Idec, Cambridge, Massachusetts) is a recombinant humanized monoclonal antibody that binds to the ₄ chain of the ₄β₁ and ₄β₇ integrins. Natalizumab reduces the extravasation of T lymphocytes, B lymphocytes, and plasma cells into the central nervous system.^3-4 We tested the association between lymphocyte numbers in the peripheral blood and cerebrospinal fluid (CSF) and the frequency of PLPH in patients with relapsing-remitting multiple sclerosis who were receiving natalizumab therapy and 14 months after cessation of therapy.

Methods

Patients

. . . [Full Text of this Article]

Lumbar Puncture and Cell Analysis

Statistical Analyses

Results
Patients

Post–Lumbar Puncture Headache

Cell Numbers in Peripheral Blood and CSF

Comment

AUTHOR INFORMATION